ミッション

 

私たちは、イノベーション、科学的な厳密さ、誠実さに基づき、創薬及び医薬品の初期開発に取り組んでいます。そして私たちのゴールは、神経疾患の発生・進行・退縮をこれまで以上に検出できる新たな画像診断技術や、神経疾患のよりよい治療につながる新たな治療方法といった、患者さんが特に必要としている新たな価値を生み出すことにあります。

 
 

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

 

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles. 
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.

Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils. 

Alpha-synuclein aggregates are found in major families of synucleinopathies, which include  Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA).

 
 
 
 

News

August 29, 2019

APRINOIA Therapeutics社は、東京の慶應義塾大学とのコラボレーションを開始しました

APRINOIA Therapeutics社(以下、アプリノイア)は、東京の慶應義塾大学とのコラボレーションを開始しました。その中でアプリノイアのタウPETイメージングトレーサー18F-APN-1607(PM-PBB3)が認知症患者のプロファイリングに使用されます。このコラボレーションは、AMED(国立研究開発法人日本医療研究開発機構)の課題番号JP17pc0101006の支援を受け慶應義塾大学とエーザイ株式会社の産医連携拠点であるエーザイ・慶應義塾大学 認知症イノベーションラボ(EKID, Eisai-Keio Innovation Laboratory for Dementia)で実施される研究の一部であります。アプリノイアは、認知症、特にアルツハイマー病の理解を深めるのに役立つ研究に貢献する機会を得たことに感謝しています。

June 30, 2019

APRINOIA TherapeuticsがJLABS @ Shanghaiに参加

APRINOIA Therapeuticsは、神経変性疾患の治療薬と画像診断のパイプラインを持つ臨床開発段階のバイオテクノロジー企業で、本日Johnson&Johnson InnovationのJLABSに加盟することが決定し、これよりJLABS @ Shanghaiの常駐企業となります。


詳細については、Johnson&Johnson Innovationのオリジナルプレスリリースの「More」をご覧ください。

May 22, 2019

APRINOIA Therapeutics社がパーキンソン病の研究に対してMichael J. Fox財団から助成金を授与される

神経変性疾患の治療薬と画像診断薬のパイプラインを持つ臨床段階のバイオテクノロジー企業であるAPRINOIA Therapeutics社は、本日、Michael J. Fox財団からパーキンソン病のαシヌクレインPETイメージングトレーサー研究のための研究開発助成金(MJFF)を授与されたと発表しました。

March 25, 2019

2019 Taiwan Top 10 Coolest Tech Startups

APRINOIA was awarded as one of the top ten most innovative startups of Taiwan in 2019 by the Ministry of Science & Technology.

December 27, 2018

2019 Human Amyloid Imaging Conference

APRINOIA will be presenting the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.

December 24, 2018

APRINOIA社のタウPETトレーサーAPN-1607の Celgene社へのライセンスについて

本日、神経変性疾患に対する治療薬およびイメージング診断薬を開発しているAPRINOIA Therapeutics社は、Celgene社と非独占的ライセンス契約を結んだことを発表した。本契約は、 [18F]でラベルされた新規タウPETトレーサーAPN-1607をCelgene社がグローバルな臨床試験における患者選択や効果判定に使用するというものであり。

October 11, 2018

Emerging Company Profile - APRINOIA TACKLES TAU

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

August 31, 2018

Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference

APRINOIA will be sponsoring the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.

December 14, 2017

APRINOIA Closes US$11.1 Million Series B Financing

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.

December 14, 2017

APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation

APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.

December 14, 2017

2018 AAT-AD/PD Focus Meeting

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.

January 01, 2020

2018 Human Amyloid Imaging Conference

APRINOIA will be presenting the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.

December 11, 2016

2017 International Conference on Alzheimer's Disease and Parkinson's Disease

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.

December 11, 2016

2017 Human Amyloid Imaging Conference

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.

December 04, 2016

2016 Taiwan Neuroscience Conference

APRINOIA is proud to host 2016 Taiwan Neuroscience Conference with Development Center for Biotechnology (DCB) and Academia Sinica on the 5th December 2016.

November 19, 2016

US FDA IND

APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.

Please reload

 
 

Careers

This information will be updated shortly.
 

お問い合わせ

台灣

Email         : contact@aprinoia.com 

地址           : 11503 臺北市南港區園區街3號17樓 

辦公室電話: +886-2-2655-8868

Taiwan


Address      17F, No.3, Park St., Nangang District, Taipei City 11503

Phone        +886-2-2655-8868

------------------------------------------------------------------------------------------

 

中国大陆

邮箱           : contact@aprinoia.com 
地址           : 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123

办公室电话:+86-512-8777 8382

China

Address      R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215123

Phone        +86-512-8777 8382

------------------------------------------------------------------------------------------------


日本

Email         : contact@aprinoia.com

所在地       : 〒104ー0033 東京都中央区新川1-2-8 第5山京ビル5F

Tel             : 03-6280-4277

Japan

Address     : Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan

Phone        : +81-3-6280-4277